Epizyme (NASDAQ:EPZM)‘s stock had its “outperform” rating restated by stock analysts at Wedbush in a research report issued to clients and investors on Wednesday, March 14th. They presently have a $25.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $26.00. Wedbush’s price objective points to a potential upside of 68.35% from the company’s current price.
Other research analysts also recently issued reports about the company. Morgan Stanley assumed coverage on Epizyme in a research note on Wednesday, January 10th. They issued an “overweight” rating and a $20.00 price target on the stock. SunTrust Banks reiterated a “buy” rating and set a $27.00 target price on shares of Epizyme in a research report on Wednesday, March 14th. Oppenheimer set a $26.00 target price on Epizyme and gave the stock a “buy” rating in a research report on Tuesday, December 12th. BidaskClub downgraded Epizyme from a “buy” rating to a “hold” rating in a research report on Saturday, February 24th. Finally, Roth Capital started coverage on Epizyme in a research report on Thursday, February 1st. They set a “buy” rating and a $24.00 target price on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $23.50.
Shares of NASDAQ EPZM opened at $14.85 on Wednesday. Epizyme has a fifty-two week low of $9.30 and a fifty-two week high of $21.40. The stock has a market cap of $1,194.37, a PE ratio of -6.81 and a beta of 1.96.
Epizyme (NASDAQ:EPZM) last announced its earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.05. Epizyme’s quarterly revenue was down 100.0% on a year-over-year basis. research analysts forecast that Epizyme will post -2.37 earnings per share for the current fiscal year.
In other news, COO Matthew Ros sold 72,264 shares of the company’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $16.63, for a total value of $1,201,750.32. Following the completion of the sale, the chief operating officer now owns 74,867 shares of the company’s stock, valued at $1,245,038.21. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 25.20% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. JGP Global Gestao de Recursos Ltda. acquired a new stake in Epizyme during the third quarter valued at approximately $292,000. Teacher Retirement System of Texas acquired a new stake in Epizyme during the fourth quarter valued at approximately $202,000. Fox Run Management L.L.C. raised its stake in Epizyme by 64.7% during the fourth quarter. Fox Run Management L.L.C. now owns 19,275 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 7,575 shares in the last quarter. Bailard Inc. acquired a new stake in Epizyme during the fourth quarter valued at approximately $251,000. Finally, MetLife Investment Advisors LLC acquired a new stake in Epizyme during the fourth quarter valued at approximately $263,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/epizyme-epzm-price-target-cut-to-25-00.html.
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.